ReNeuron Group plc Block Listing Review, Application and TVR (5573K)
02 Septiembre 2021 - 06:00AM
UK Regulatory
TIDMRENE
RNS Number : 5573K
ReNeuron Group plc
02 September 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review, Block Listing Application
and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, provides the following
update in accordance with Schedule Six of the AIM Rules for
Companies regarding its existing block listing arrangements.
Name: ReNeuron Group plc
Name of Scheme: ReNeuron Share Option Schemes
--------------------------------------
Period of Return: From 1 March 2021 to 31 August 2021
--------------------------------------
Balance of unallotted securities 663,687 Ordinary Shares (of 1p each)
under scheme(s) from previous
return:
--------------------------------------
Plus : The amount by which N/A
the block scheme(s) has been
increased since the date
of the last Review (if any
increase has been applied
for):
--------------------------------------
Less : Number of securities
issued/allotted under scheme(s)
during period 80,697
--------------------------------------
Equals : Balance under scheme(s) 582,990 Ordinary Shares
not yet issued/allotted at
end of period:
--------------------------------------
Number and class of securities 20,000 ordinary shares on 13 May 2010
originally admitted and the
date of admission:
--------------------------------------
Block Listing Application
Given the number of options under the existing Share Option
Scheme, the Company announces that it has made an application to
the London Stock Exchange for a block listing of 3,000,000
additional new ordinary shares of 1p each in the capital of the
Company ("Ordinary Shares") to be admitted to AIM.
The Ordinary Shares will be issued from time to time pursuant to
the Company's existing plans including outstanding options already
issued but not yet exercised to the employees of the Company.
When issued, the Ordinary Shares under this block listing will
rank pari passu with the Company's existing issued Ordinary Shares.
It is expected that admission will be effective on 3 September
2021.
Total Voting Rights
At 31 August 2021, the Company had 56,936,402 Ordinary Shares in
issue, each carrying one voting right.
As the Company holds no ordinary shares in treasury, the figure
of 56,936,402 may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAENAESAFEFA
(END) Dow Jones Newswires
September 02, 2021 07:00 ET (11:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024